Antifibrinolytic agent
The company is developing the agent to reduce bleeding in life-threatening and disabling haemorrhagic conditions.
Source: LinkedIn company description · Retrieved October 13, 2026
Hemostatics is developing an antifibrinolytic agent for bleeding conditions.
Its patented candidate is preclinical and aims to address needs in trauma, surgery, intracerebral haemorrhage, postpartum haemorrhage, gastrointestinal bleeding and several bleeding disorders. The candidate is described as acting to inhibit fibrinolysis.
Based on the company’s public LinkedIn information, supplied through RevenueBase.
The company is developing the agent to reduce bleeding in life-threatening and disabling haemorrhagic conditions.
Source: LinkedIn company description · Retrieved October 13, 2026
Supported appearances on published RevenueBase lists, including available memberships beyond displayed rankings.
Positions describe ordering within each source list. See how lists are built ↗
Embeddable award for your website
RevenueBase prepared this profile from the company’s public LinkedIn information and RevenueBase company data. These source records were retrieved on October 13, 2026. AI helped summarize these sources, with a separate automated check against the source text completed on November 4, 2026. Directory positions use company-contact counts from separate saved list snapshots dated September 19, 2026. How the company lists are built.
Share a correction, your relationship to the company, and supporting sources. Requests are reviewed before changes are published.
Explore more companies by name, headquarters and business focus.